Table 1. Patient characteristics.
| Patient characteristics | All (N=103) | Docetaxel + bevacizumab (N=51) | Pemetrexed + bevacizumab (N=52) |
|---|---|---|---|
| Median age [range] | 79 [75–94] | 78 [75–88] | 79 [75–94] |
| Sex (male/female) | 62/41 | 33/18 | 29/23 |
| Smoking status (current or past/never) | 61/42 | 30/21 | 31/21 |
| ECOG PS (0/1) | 48/55 | 24/27 | 24/28 |
| Clinical stage (IIIB/IV/recurrent) | 7/68/28 | 4/33/14 | 3/35/14 |
| Histologic subtype (ADC/LCC/others) | 96/1/6 | 47/0/4 | 49/1/2 |
| Brain metastasis (yes/no) | 15/88 | 7/44 | 8/44 |
| EGFR mutational status (mutation/wild-type/unknown) | 28/71/4 | 14/35/2 | 14/36/2 |
| ALK translocation (yes/no/unknown) | 3/82/18 | 1/40/10 | 2/42/8 |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; ADC, adenocarcinoma; LCC, large cell carcinoma; EGFR, epidermal growth factor receptor; ALK anaplastic lymphoma kinase.